Table IV.
Proportion of APB-positive IIICF-T/B3 cells after siRNA treatment
| siRNA treatmenta | Total (SV40T−)b | APB+ (%) |
| SV40T + C | 117 | 63 (53.8) |
| SV40T + HP1α | 111 | 40 (36.0) |
| SV40T + HP1α-2 | 120 | 38 (31.7) |
| SV40T + HP1β-1 | 123 | 56 (45.5) |
| SV40T + HP1β-4 | 124 | 61 (49.2) |
| SV40T + HP1γ-2 | 109 | 38 (34.9) |
| SV40T + HP1γ-6 | 128 | 41 (32.0) |
| SV40T + C + C | 94 | 53 (56.4) |
| SV40T + C + p21-6 | 98 | 25 (25.5) |
| SV40T + C + HP1α | 97 | 33 (34.0) |
| SV40T + C + HP1β-1 | 100 | 47 (47.0) |
| SV40T + C + HP1γ-6 | 106 | 30 (28.3) |
| SV40T + HP1α + HP1β-1 | 105 | 32 (30.5) |
| SV40T + HP1α + HP1γ-6 | 110 | 24 (21.8) |
| SV40T + HP1β-1 + HP1γ-6 | 99 | 31 (31.3) |
| SV40T + C + C | 111 | 58 (52.3) |
| SV40T + C + HP1α-2 | 106 | 32 (30.2) |
| SV40T + HP1α-2 + HP1α-2 | 119 | 33 (27.7) |
| SV40T + HP1α-2 + HP1γ-6 | 107 | 21 (19.6) |
C, nonsilencing control siRNA.
a
Cells were treated with 10 nM siRNA per target for 4 d before being fixed for immunostaining.
b
Only cells that were negative by immunostaining for SV40T were examined for APBs.